Post Traumatic Stress Disorder Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Post Traumatic Stress Disorder Treatment Market is segmented by Drug Type (Antidepressants, Monoamine Oxidase Inhibitors, Antipsychotics or Second-Generation Antipsychotics, Beta-blockers, Benzodiazepines, and Others), Age Group (Adult and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Post Traumatic Stress Disorder Treatment Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: Asia-Pacific
CAGR: 4.35 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The post-traumatic stress disorder treatment market is expected to register a CAGR of 4.35% during the forecast period, 2022 - 2027.

COVID-19 has considerably impacted the demand for post-traumatic stress disorder (PTSD) treatment due to the rise in stress among patients regarding the COVID-19 pandemic. For instance, according to the study published in the International Journal of Mental Health Nursing, titled "Impact of COVID‐19 on post‐traumatic stress symptoms in the general population: An integrative review" in April 2021, in most investigations, a high and wide range of PTSD rates were recorded. Similar to the findings of studies on other infectious diseases, the study concluded that the post-traumatic stress symptoms impacted the entire population exposed to the SARS-CoV-2 virus. Furthermore, according to the study published in the Journal of Affective Disorders, titled "The prevalence of post-traumatic stress disorder related symptoms in Coronavirus outbreaks: A systematic review and meta-analysis", in January 2021, the prevalence of PTSD symptoms was estimated to be about 18%. This is expected to increase the adoption of PTSD therapies during the pandemic phase, which in turn has a positive impact on the market growth.

Further, the major factors driving the market's growth include a rise in the burden of post-traumatic stress disorders across the globe, growth in research and development for PTSD, a surge in product launches and developments, and an increasing number of strategic initiatives undertaken by key market players.

An upsurge in the incidences of post-traumatic stress disorders worldwide is one of the major factors driving the market growth. For instance, according to the post-traumatic stress disorder factsheet published in October 2021 by NeuRA (Neuroscience Research Australia), the general population's lifetime prevalence of PTSD was approximately 3.9 percent. In those who had been exposed to trauma, the rate was 5.6 percent. The prevalence of PTSD in people who have been subjected to purposeful traumas such as war and assault (rather than non-intentional traumas such as accidents and natural catastrophes) increased, with rates rising from 11.8 percent in one month to 23.3 percent in one-year post-trauma. Thus, such a growing prevalence of PTSD is anticipated to impact the market's growth positively.

Additionally, the rise in research and development activities by the key market players will lead to an increase in clinical trials for the development of PTSD drugs, ultimately boosting the commercial availability of products within the market. For instance, in December 2021, Jazz Pharmaceuticals plc was enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). Therefore, a rise in clinical trials, growth in research and development activities, and a surge in the prevalence of PTSD are all collectively expected to drive this market's growth.

However, a lack of awareness among people about PTSD treatments, as well as side effects associated with PTSD therapeutics, is expected to hinder the market's growth during the analysis period.

Scope of the Report

As per the scope of the report, post-traumatic stress disorder (PTSD) is a treatable anxiety disorder caused due to fear, anxiety, and memories of a traumatic event. It is characterized by symptoms such as flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. People who have encountered or witnessed a traumatic incident such as a natural disaster, a catastrophic accident, a terrorist attack, war/combat, or who have been threatened with death, sexual violence, or serious injury may develop post-traumatic stress disorder (PTSD). The market is segmented by Drug Type (Antidepressants, Monoamine Oxidase Inhibitors, Antipsychotics or Second-Generation Antipsychotics, Beta-blockers, Benzodiazepines, Others), Age Group (Adult and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Drug Type
Antidepressants
Monoamine Oxidase Inhibitors
Antipsychotics or Second generation Antipsychotics
Beta-blockers
Benzodiazepines
Others
Age Group
Adult
Children
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antipsychotics or Second generation Antipsychotics Drugs Segment Is Expected To Hold A Major Share In The Market Studied

By drug type, the antipsychotics or second-generation antipsychotic drugs segment is expected to hold a major share in the post-traumatic stress disorder treatment market owing to the rise in the adoption of antipsychotic drugs for the treatment of PTSD and PTSD-related symptoms.

The presence of psychotic symptoms in individuals suffering from PTSD has led researchers to encourage the recognition of a variant of PTSD known as PTSD with psychotic features and its subsequent treatment with antipsychotic medication. A typical antipsychotic has been shown to be effective in the treatment of PTSD in several studies. While some studies show an improvement in sleep patterns, including a decrease in nightmares, others show an improvement in flashbacks and intrusive thoughts. Likewise, as per a study published in Frontiers in Pharmacology, titled "Comparative Efficacy and Acceptability of Pharmaceutical Management for Adults With Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis" in May 2020, a typical antipsychotic showed considerable efficacy when compared to placebo in patients with severe or extremely severe PTSD. The substantial effectiveness of antipsychotics in PTSD will lead to increased adoption of antipsychotics for the treatment of PTSD, driving this segment's growth.

In addition, according to study results presented at Psych Congress 2021 in San Antonio, Texas, adjunctive bexpiprazole (an antipsychotic drug) may help individuals with symptoms of anxious distress disorders such as PTSD. Furthermore, key market players are developing antipsychotic drugs for the treatment of PTSD. For instance, Otsuka Holding is developing Rexulti (bexpiprazole), and the molecule is under phase III clinical studies as of March 2022.

Therefore, the increasing adoption of antipsychotic drugs for the treatment of PTSD, the rise in clinical trials for antipsychotic drugs, and the notable efficacy of antipsychotics in the treatment of PTSD are the factors expected to drive the growth of this segment over the forecast period.

Post Traumatic Stress Disorder Treatment Market Share

North America Holds a Major Share and Expected to do Same in the Forecast Period

The North American region is expected to garner a significant share of the market and is expected to dominate the market over the forecast period. The major factors driving the growth in this region include a rise in the prevalence of PTSD, a sophisticated healthcare system, the strong foothold of key market players, and high investments in research and development activities. According to the data published by the United States Department of Veterans Affairs-National Center for PTSD, updated in April 2022, around 6 out of every 100 people will develop PTSD in their lifetime. As per the same source, almost 12 million adults in the United States suffer from PTSD. This represents a small percentage of people who have experienced a traumatic event. PTSD affects approximately 8 out of every 100 women, compared to approximately 4 out of every 100 men. Such an increased prevalence of this disorder is therefore expected to drive the market growth in this region.

In addition, in January 2021, Mount Sinai's Icahn School of Medicine opened a new psychedelic research center. The Center for Psychedelic Psychotherapy and Trauma Research takes a multifaceted therapeutic and research approach to the discovery of new and more effective treatments for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related illnesses in veterans and civilians. Such initiatives for the protection of psychic health will therefore lead to increased adoption of PTSD therapies in this region, driving the market growth in North America.

Furthermore, growing strategic initiatives will impact the market's growth positively. For instance, in August 2020, ATAI Life Sciences, a biotech firm focused on developing psychedelic and non-psychedelic compounds for a variety of mental health indications, launched EmpathBio, a wholly-owned subsidiary focused on developing MDMA derivatives for the treatment of PTSD and other conditions in the United States.

Therefore, owing to the abovementioned developments, the market is expected to drive in this region.

Post Traumatic Stress Disorder Treatment Market Growth

Competitive Landscape

The market for post-traumatic stress disorder is moderately competitive. The factors driving the growth of this market include the increase in research funding for PTSD, the growth in the launch of newer products for PTSD, and the rise in clinical trials, among others. Some of the major players in this market include Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceuticals Pvt. Ltd., Johnson & Johnson, GlaxoSmithKline PLC, Pfizer Inc., Amneal Pharmaceuticals LLC, and Apotex Inc., among others.

Recent Development

In March 2022, Apex Lab Ltd. received a No Objection Letter ("NOL") from Health Canada regarding its phase 2a Clinical Trial Application ("CTA") protocol APEX-002-A01. This CTA approval is for a randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, and efficacy of psilocybin in veterans with post-traumatic stress disorder using drug product APEX-002-A01.

In February 2022, Lundbeck teamed up with Mental Health America to tackle the other COVID-19 crisis. The collaboration is operating a new dashboard in the United States that shows where mental health is most at risk on a local level. Suicidal ideation, severe depression, post-traumatic stress disorder (PTSD), trauma, and psychosis are among the topics covered by the dashboard.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 The Rising Prevalence of Post-Traumatic Stress Disorder

      2. 4.2.2 Rising Number of Clinical Trials for New Drug Development for the Treatment Of Post-Traumatic Stress Disorder

    3. 4.3 Market Restraints

      1. 4.3.1 The Lack of Information and Awareness

      2. 4.3.2 High Prices of Treatment and Side Effects of Specified Medicine

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 Drug Type

      1. 5.1.1 Antidepressants

      2. 5.1.2 Monoamine Oxidase Inhibitors

      3. 5.1.3 Antipsychotics or Second generation Antipsychotics

      4. 5.1.4 Beta-blockers

      5. 5.1.5 Benzodiazepines

      6. 5.1.6 Others

    2. 5.2 Age Group

      1. 5.2.1 Adult

      2. 5.2.2 Children

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 Otsuka Pharmaceutical Co., Ltd.

      4. 6.1.4 Eli Lilly and Company

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Sun Pharmaceuticals Pvt Ltd.

      7. 6.1.7 Johnson and Johnson

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Amneal Pharmaceuticals LLC

      10. 6.1.10 Apotex Inc.

      11. 6.1.11 Teva Pharmaceuticals Industries Ltd.

      12. 6.1.12 Viatris Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Post Traumatic Stress Disorder Treatment Market market is studied from 2019 - 2027.

The Global Post Traumatic Stress Disorder Treatment Market is growing at a CAGR of 4.35% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia-Pacific holds highest share in 2021.

Otsuka Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Pfizer Inc., Apotex Inc, Amneal Pharmaceuticals LLC are the major companies operating in Global Post Traumatic Stress Disorder Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!